APPLICATION FRONTIER
Resorption cannot compensate for poor vascular outcomes.
DIRECT ANSWER
Bioresorbable vascular scaffolds were developed to provide temporary support inside a vessel and subsequently degrade. Cardiovascular use is technically demanding because radial strength, strut thickness, healing response and antithrombotic strategies influence patient outcomes.
WORKING PRINCIPLES
Polymer scaffold designs combine a temporary mechanical framework with controlled breakdown. The performance window must be matched to vessel remodeling. Unlike a conventional permanent metal stent, the scaffold changes mechanically and geometrically over time, introducing additional validation needs.
TRANSLATIONAL REALITY
The FDA granted approval to the ABSORB GT1 bioresorbable vascular scaffold in July 2016 and records withdrawal on May 11, 2023. That sequence is a central lesson: an initially approved resorbable technology can face significant post-market and clinical limitations. This page is not a recommendation for any vascular device.
DESIGN CONSTRAINTS
Thrombotic risk, scaffold geometry and vessel size matter.
Regulatory approval and continued marketing are distinct milestones.
Other emerging scaffold designs require independent clinical evaluation.
DIRECT ANSWERS
Yes. The ABSORB GT1 system received US FDA approval in 2016, but its approval was subsequently withdrawn in 2023.
No. Safety and efficacy depend on the exact device and supporting clinical evidence.
A scaffold must support the vessel mechanically without introducing unacceptable thrombosis or healing risks.
REFERENCES
Selected primary records and peer-reviewed literature relevant to the exact material or application.